I-Corps: Biodegradable Airway Stent for Tracheal Stenosis Management

I-Corps：用于气管狭窄管理的可生物降解气道支架

• 批准号: 1748674
• 负责人: Prashant Kumta
• 金额: $ 5万
• 依托单位: University of Pittsburgh
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-01-01 至 2018-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1748674&HistoricalAwards=false
• 关键词: Corps; Biodegradable; Airway; Stent; Tracheal

The broader impact/commercial potential of this ICorps project is to prevent complications developing from the use of non-degradable permanent implants and ultimately reduce redo/replacement procedures in the healthcare field. The introduction of a novel family of biodegradable medical implants meets this intention. There is a sizeable market for biodegradable devices to treat various health conditions and address issues from existing therapeutics. The global biodegradable stent market is expected to grow significantly over the next ten years. Mortality from heart diseases and cancer is projected to increase through the year 2020. However, with appropriate minimally-invasive intervention, the number of deaths can potentially be reduced significantly. The high cost of follow-up procedures due to insertion of permanent stents urges healthcare industry to seek better alternatives. The ultimate goal is to boost the position of the United States as a leader in the global absorbable device market.This I-Corps project focuses on a biomaterial, a novel biodegradable magnesium based alloy that can be used to design and develop the biodegradable medical devices. Magnesium is already present in the human body and simply degrades safely from the stents over time. The invention provides a material composition for medical device like stents. The invented material exhibits high ductility and corrosion resistance acceptable for all medical devices requiring plasticity and ductility exceeding that of conventional magnesium alloys. Many disease complications in adults constrict or block a passage within the body, causing symptoms and wellness deterioration. Although surgical correction is preferred when technically feasible and permitted by the clinical status of patient, stenting is often a reliable alternative. Recent research has indicated that innovative technology platform points to safe and cost-effective biodegradable metallic stents, and will solve the problems caused by existing stents made of permanent materials like silicone, nitinol and polymers.

该ICorps项目的更广泛影响/商业潜力是防止使用不可降解永久性植入物引起的并发症，并最终减少医疗保健领域的重做/更换手术。引入一种新的可生物降解的医疗植入物家族符合这一意图。生物可降解设备有相当大的市场，可以治疗各种健康状况并解决现有治疗方法的问题。全球可生物降解支架市场预计将在未来十年内显着增长。 预计到2020年，心脏病和癌症的死亡率将增加。然而，通过适当的微创干预，死亡人数可能会显着减少。 由于插入永久性支架导致的后续程序的高成本促使医疗保健行业寻求更好的替代方案。最终目标是提升美国作为全球可吸收器械市场领导者的地位。该I-Corps项目专注于一种生物材料，一种新型可生物降解的镁基合金，可用于设计和开发可生物降解的医疗器械。镁已经存在于人体中，并且随着时间的推移会从支架中安全降解。本发明提供了一种用于医疗器械如支架的材料组合物。本发明的材料表现出可接受的高延展性和耐腐蚀性，可用于所有需要超过常规镁合金的塑性和延展性的医疗器械。成人的许多疾病并发症会收缩或阻塞体内通道，导致症状和健康恶化。尽管在技术可行且患者临床状况允许的情况下，首选手术矫正，但支架植入术通常是可靠的替代方案。最近的研究表明，创新的技术平台指向安全和具有成本效益的可生物降解金属支架，并将解决现有支架由硅树脂，镍钛诺和聚合物等永久性材料制成的问题。